Medindia
Medindia LOGIN REGISTER
Advertisement

Amilpar -- Consolidated Revenues Grow 64% and EBITDA Increases 44% in the Quarter Compared to the Previous Year

Wednesday, May 12, 2010 Drug News
Advertisement
RIO DE JANEIRO, May 11 Amilpar (BM&FBOVESPA: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest Healthcare company in Brazil, announced today its results for the first quarter of 2010 (1Q10).
Advertisement

Amil's Results (without the effect of Medial)

Medial's Results

Results in accordance with BR GAAP (consolidated with Medial)

To access the Earnings Release full version visit our website at www.amilpar.com.br/ir
Advertisement

Next Events: Conference Calls

English

May 12, 2010

10 AM (New York)

(11 AM Brasilia)

Phone: +1 (412) 858-4600

Code: Amil

Webcast: www.amilpar.com.br/ir

Portuguese

May 12, 2010

1 PM (New York)

(2 PM Brasilia)

Phone: +55 (11) 2188-0155

Code: Amil Webcast: www.amilpar.com.br/ri

IR Contact

Erwin Kleuser

Investor Relations Officer

Phone: +55 (21) 3805-1155

[email protected]

www.amilpar.com.br/ir

About Amilpar

Amil Participacoes S.A. is the largest managed care organization in Brazil, according to the ANS, currently assisting over 5 million members in the states of Sao Paulo, Rio de Janeiro, Parana, Minas Gerais, Pernambuco, Bahia and in Distrito Federal.

-- Adjusted Operating Revenues totaled R$ 1,290.8 million in the first quarter of 2010, a growth of 14.1% compared to same period of the previous year, and 2.8% over the 4Q09. -- Adjusted EBITDA came to R$ 138.3 million (10.7% margin) in 1Q10, 15.7% above the R$ 119.5 million (10.6% margin) recorded in 1Q09. -- The Company posted adjusted Net Income of R$ 67.0 million in the first quarter, 15.0% down on the same period last year, mainly due to lower net financial result as a consequence of the cash disbursed for Medial's acquisition.

SOURCE Amilpar
Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close